Neutralizing IgG antibodies

Determination of neutralizing antibodies after vaccination


The publication by Eberhardt KE et al. (Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG, Microorganisms 2021 March 31; 9(4):733) proves that our IDK® anti-SARS-CoV-2 IgG ELISA (K 5004) achieves the highest sensitivity among S-protein based assays in the detection of anti-SARS-CoV-2 IgG antibodies after COVID-19 recovery. The assay correlates better with neutralization than the competition and detects even the lowest concentrations of neutralizing antibodies. In addition, internal validation studies have shown that the test is excellent for detecting an immune response after COVID-19 vaccination. Therefore, the IDK® anti-SARS-CoV-2 IgG ELISA is ideally suited for the quantitative detection of neutralizing antibodies after COVID-19 vaccination.

In a Focus report, Andreas Bobrowski, head of laboratory physicians, explains at which antibody level the value is high enough – and when a third vaccination makes sense.

As a guideline, Bobrowski assumes the following limits:

  • Antibody level < 21.8 BAU: the person has a high probability of no immune protection against Corona.
  • Antibody level > 44 BAU: the person has a high probability of immune protection against Corona.
  • Antibody level > 1000 BAU: the person can be assumed to have full protection; but, Bobrowski generally advises against third party vaccination.


Subscribe to Newsletter

Would you like to be informed about the latest news in the future? Then simply subscribe to our newsletter.

Register Don't show this again

This might also be of interest